Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381680 · ClinicalTrials.gov registry record · Phase 3
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
NCT00381680 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 275 participants.
The verdict
NCT00381680, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways and different doses may kill more cancer cells..
Interventions
- DRUG prednisone
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
- DRUG vincristine sulfate
- DRUG pegaspargase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381680
The ClinicalTrials.gov registry entry for NCT00381680 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00381680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381680 about?
NCT00381680 is a clinical study titled "Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia". This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs use...
What is the current status of trial NCT00381680?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2007-03.
What interventions are being tested in trial NCT00381680?
The interventions under investigation include: prednisone (DRUG), doxorubicin hydrochloride (DRUG), cytarabine (DRUG), vincristine sulfate (DRUG), pegaspargase (DRUG).
Who is sponsoring clinical trial NCT00381680?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.